The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by The Fly.
Top 5 Upgrades:
-
B. Riley upgraded Airbnb (ABNB) to Buy from Neutral with a price target of $170, up from $140. The firm cites the stock’s attractive valuation and the company’s prospects for sustained “healthy” growth and margin expansion.
-
Citi upgraded Palantir (PLTR) to Buy from Neutral with a price target of $235, up from $210. The firm sees 2026 bringing significantly higher consensus estimates for Palantir.
-
BofA upgraded Comcast (CMCSA) to Buy from Neutral with a price target of $37, up from $31. The media and cable landscape enters 2026 amid significant structural change, which sets the stage for “a transformative year” marked by industry consolidation, evolving distribution strategies, and emerging opportunities across content, technology, and live experiences, the firm said.
-
Citi upgraded Zoom Communications (ZM) to Buy from Neutral with a price target of $106, up from $94. The firm views the stock’s valuation as “undemanding” given the company’s path to “sustainable” 5% sales growth.
-
Morgan Stanley upgraded Datadog (DDOG) to Overweight from Equal Weight with an unchanged price target of $180. The firm says the company’s underlying growth trends heading into 2026 are improving.
Top 5 Downgrades:
-
Wolfe Research downgraded Rivian (RIVN) to Underperform from Peer Perform with a $16 price target. The risk/reward appears unfavorable at current levels, as Rivian’s fundamentals have weakened despite recent share gains driven by autonomy enthusiasm, with 2026 Street expectations viewed as overly optimistic, the firm says.
-
Barclays downgraded Snowflake (SNOW) to Equal Weight from Overweight with a price target of $250, down from $290. Barclays cites valuation for the downgrade of Snowflake following the stock’s 42% rally in 2025.
-
Barclays downgraded Insulet (PODD) to Underweight from Equal Weight with a price target of $274, down from $316. As new competition approaches in the tubeless and patch-up automated insulin delivery category, Insulet’s multiple will see further pressure, the firm tells investors in a research note.
-
TD Cowen downgraded Allstate (ALL) to Hold from Buy with a price target of $231, up from $224. The company’s competition has heightened for personal auto policy-in-force, the firm tells investors in a research note.
-
KeyBanc downgraded CrowdStrike (CRWD) to Sector Weight from Overweight without a price target as part of its 2026 outlook for the security, data and AI software names. CrowdStrike is facing “more balanced security spend intentions,” as indicated by the survey, the firm tells investors in a research note.
